Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

38
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
38
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

COVID-19 Vaccine-triggered Relapsing Immune Dysregulation: An Observational Study with Four-year Follow-up.

Annals of neurosciences·2026
Same author

Livestock-associated antimicrobial resistance and its implications for human health in India: A one health perspective.

Indian journal of medical microbiology·2026
Same author

Mesenchymal stromal/stem cells in tumour initiation, progression and therapy.

Nature reviews. Cancer·2026
Same author

The Unusual Suspects: Macrophages in Parkinson's Disease?

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Adapting covid-19 vaccination through targeted approaches: FDA-approved vaccines for the 2025-2026 season.

Immunologic research·2026
Same author

Evaluating senescence-targeted approaches in Alzheimer's Disease: What we know and what lies ahead.

Ageing research reviews·2026

相关实验视频

Updated: Sep 10, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.7K

基于智能手机的数字健康干预:对心血管和脑血管结果的综合系统性审查

Swathi Suresh1, Sujas Bhardwaj1, Hansel Chris Rodrigues1

  • 1Centre for Brain Research, Indian Institute of Science, CV Raman Avenue, Bengaluru, 560012, Karnataka, India.

Journal of medical systems
|August 26, 2025
PubMed
概括
此摘要是机器生成的。

数字卫生干预措施对控制心血管和脑血管疾病的风险因素具有前景. 然而,复杂的临床结果需要个性化的方法和更好的参与,以提高有效性.

关键词:
心血管疾病脑血管疾病数字卫生干预措施医疗卫生移动健康远程监控患者自主管理基于智能手机的数字健康干预

更多相关视频

An Application for Pairing with Wearable Devices to Monitor Personal Health Status
06:58

An Application for Pairing with Wearable Devices to Monitor Personal Health Status

Published on: February 3, 2022

2.9K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

相关实验视频

Last Updated: Sep 10, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.7K
An Application for Pairing with Wearable Devices to Monitor Personal Health Status
06:58

An Application for Pairing with Wearable Devices to Monitor Personal Health Status

Published on: February 3, 2022

2.9K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

科学领域:

  • 数字健康
  • 心血管疾病
  • 脑血管疾病

背景情况:

  • 数字卫生干预措施 (DHIs) 具有控制心血管疾病 (CVD) 和脑血管疾病 (CeVD) 风险因素的潜力.
  • 整合到医疗保健需要了解DHI的临床有效性,实施挑战和可用性.

研究的目的:

  • 评估基于智能手机的CVD和CeVD治疗的临床疗效.
  • 确定与这些DHI相关的功能和障碍.

主要方法:

  • 在PROSPERO (CRD42024570866) 中注册的系统审查.
  • 搜索了PubMed,科学直播,科学网络, DOAJ.
  • 使用Cochrane的RoB2和ROBINS-I评估研究质量.

主要成果:

  • 包括35项研究,主要是来自高收入国家的随机对照试验 (RCT).
  • 身体活动显著改善.
  • 血压,葡萄糖,脂质和体重的结果各不相同;许多结果在统计学上并不显著.

结论:

  • DHI显示了控制心血管疾病和心血管疾病风险因素的潜力.
  • 结果的变化表明需要个性化干预.
  • 较长的研究和改进的参与策略对于有效性和可扩展性至关重要.